$148 million plus $100 million debt. Where are they going to get the money. Senea already heavily leveraged. 1:1 debt to equity? Add 248 million debt ? 1.5 debt to equity . Shareholders getting forked.
Two years ago they tried buying this money losing Allen co , Shows you what kind of management Senea has. Next to go broke will be Senea.
Next dog my pick RFMD. Another low PE semi that trades like a dog.. Actually has better growth prospect than LSI. Honorable mention in Barrons Dec 3 together with Avago.
China didn't "drew the line". China the buyer wants to buy gold as cheap as possible. US also wants gold cheap so US$ look good. Our Keynesian economists at the Treasuries and Federal Reserve have dumped gold (somebody else's gold , OURs) to prove their theory.
I think t0 can actually do it. Its only a clinical trial ,years before Geron make real dough if it wins approval. Current valuation $800 million is fairly high for a clinical stage company thus the sell off from November high. Inability to rally is the tell.
I'm hoping for gradual climb to ASH, then pop 35% on ASH. I will sell into the POP.
This was $1.20 early in the year. so sell of the news is pretty heavy. We now have two very good studies from University of Bern and Mayo Clinic. Definitely worth holding for a few years.